의약품 검사 장비 시장(-2031년) : 컴포넌트(비전 검사, X선 검사, 중량 선별기, 금속 감지기, 소프트웨어), 유형(수동, 자동), 포장 유형(주사기, 블리스터, 보틀), 제제(비경구, 경구)

The pharmaceutical inspection machines market is projected to reach USD 1.62 billion by 2031 from USD 1.14 billion in 2026, growing at a CAGR of 7.2%.

The rapid growth of the ampoules and vials segment is driven by increasing production of injectable drugs, biologics, vaccines, and sterile pharmaceutical products that require stringent quality control and inspection standards. These packaging formats are highly sensitive and demand advanced inspection technologies capable of detecting particulate contamination, cosmetic defects, fill-level inconsistencies, cracks, and seal integrity issues. AI-enabled inspection systems integrated with machine vision and high-resolution imaging technologies provide accurate real-time analysis and improve defect detection capabilities. Rising demand for parenteral formulations, coupled with stricter regulatory requirements and increasing adoption of automated pharmaceutical manufacturing, is accelerating the deployment of advanced inspection systems for ampoules and vials. Additionally, manufacturers are increasingly investing in high-speed inspection solutions to enhance operational efficiency, minimize recalls, and ensure product safety.

Based on Component:

One of the key factors driving the growth of the software and vision system segment in the Pharmaceutical Inspection Machine market is the increasing adoption of advanced machine vision, AI, and sensor technologies. Inspection systems comprise components such as cameras, sensors, robotics, conveyors, software platforms, and data analytics tools that work together to ensure accurate detection and quality assurance. High-performance imaging systems and AI-enabled software improve the identification of particulate contamination, cosmetic defects, fill-level variations, and packaging inconsistencies with greater precision. In addition, advanced software solutions reduce false rejection rates and support real-time monitoring and process optimization. As pharmaceutical manufacturers continue investing in automation and quality compliance, demand for intelligent inspection components is increasing, strengthening their role in modern pharmaceutical manufacturing environments.

Based on Formulation: One of the major factors driving the dominance of injectable and sterile formulation segments in the Pharmaceutical Inspection Machine market is the critical need for stringent quality control and patient safety. Pharmaceutical inspection machines are extensively used for formulations such as injectables, biologics, tablets, capsules, ophthalmic products, and liquid formulations to detect defects, particulate contamination, fill-level inconsistencies, and packaging errors. Injectable and sterile products require highly precise inspection due to strict regulatory requirements and the high risk associated with contamination. In addition, the growing production of biologics, prefilled syringes, and complex drug formulations has increased demand for advanced inspection systems. As pharmaceutical manufacturers continue to prioritize product integrity and compliance, inspection requirements across diverse formulation types are driving sustained market growth.

North America's well-established pharmaceutical manufacturing ecosystem plays a crucial role in driving the adoption of pharmaceutical inspection machines. The region has a strong presence of leading pharmaceutical and biotechnology companies, contract manufacturing organizations (CMOs), and advanced production facilities that require stringent quality control and regulatory compliance. Pharmaceutical manufacturers in the U.S. and Canada increasingly invest in automated inspection technologies, machine vision systems, and AI-enabled quality assurance solutions to enhance operational efficiency and ensure product safety. Additionally, strict regulatory frameworks and quality standards encourage the deployment of advanced inspection systems across production lines. The presence of strong R&D capabilities, high healthcare expenditure, and continuous investments in manufacturing modernization further support market growth. This robust pharmaceutical ecosystem ensures sustained demand and widespread adoption of pharmaceutical inspection machines across the region.

A breakdown of the primary participants (supply-side) for the pharmaceutical inspection machine market referred to in this report is provided below:

• By Company Type: Tier 1:34%, Tier 2: 38%, and Tier 3: 28%
• By Designation: C-level: 26%, Director Level: 35%, and Others: 39%
• By Region: North America: 17%, Europe: 39%, Asia Pacific: 28%, Latin America: 8%, Middle East & Africa: 3%, GCC Countries: 5%

Prominent players in the pharmaceutical inspection machine market are market Korber AG (Germany), Mettler Toledo (US), Omron Corporation (Japan), Cognex Corporation (US), Stevanato Group (Italy), Antares Vision S.p.A. (Italy), Optel Group (Canada), Syntegon Technology GmbH (Germany), Jekson Vision (India), ACG (India), Brevetti CEA S.p.A. (Italy), Roquette Freres (France), Toflon Life Science (China), Prodieco (Ireland), WIPOTEC GmbH (Germany), CMP Pharma S.R.L. (Italy), Keyence Corporation (Japan), Cassel Messtechnik GmbH (Germany), Thermo Fisher Scientific Inc. (US), Loma Systems (UK), VITRONIC Dr.-Ing. Stein Bildverarbeitungssysteme GmbH (Germany), Minebea Intec GmbH (Germany), Marchesini Group S.p.A. (Italy), N.K.P. Pharma Pvt. Ltd. (India), and Span Systems (India).

Research Coverage

The report evaluates the pharmaceutical inspection machine market and estimates the market size and future growth potential of this market based on various segments, including by component, type, packaging type, formulation, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will assist the market leader/new entrants in the market with data on the nearest approximations of the revenue numbers for the overall, the pharmaceutical inspection machine market, and the subsegments. The report will assist stakeholders in understanding the competitive landscape and gain further insights into better positioning their businesses and making appropriate go-to-market strategies. The report assists the stakeholders in understanding the market pulse and gives them data on influential drivers, hindrances, obstacles, and opportunities in the market.

This report provides insights into the following points:

• Analysis of key drivers (increasing adoption of AI- and machine vision-based inspection systems, rising pharmaceutical manufacturing output, growing emphasis on stringent regulatory compliance and quality assurance, rising demand for automated inspection solutions, increasing focus on patient safety and defect reduction), restraints (high implementation and maintenance costs of advanced inspection systems, complex integration with existing manufacturing infrastructure), opportunities (growing adoption of Industry 4.0 and smart manufacturing, rising demand for pharmaceutical inspection solutions in emerging markets), and challenges (shortage of skilled professionals for operating advanced systems, managing high inspection accuracy while minimizing false rejection rates)
• Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the global pharmaceutical inspection machines market
• Market Development: Thorough knowledge and analysis of the profitable rising markets by product, application, end user, and region.
• Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global pharmaceutical inspection machines market
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global pharmaceutical inspection machines market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 SEGMENTS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 LIMITATIONS
• 1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 PHARMACEUTICAL INSPECTION MACHINES MARKET OVERVIEW
• 3.2 ASIA PACIFIC: PHARMACEUTICAL INSPECTION MACHINES MARKET, BY PRODUCT AND COUNTRY (2025)
• 3.3 PHARMACEUTICAL INSPECTION MACHINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 3.4 PHARMACEUTICAL INSPECTION MACHINES MARKET, BY REGION (2023-2030)
• 3.5 PHARMACEUTICAL INSPECTION MACHINES MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Increasing use of inspection machines by pharmaceutical and biotechnology companies
    • 4.2.1.2 Rising number of inspection checkpoint mandates
    • 4.2.1.3 Technological advancements and stringent regulatory mandates for high-quality products
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High initial capital expenditure and recurring maintenance costs
    • 4.2.2.2 Increased data security and privacy concerns
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Increasing outsourcing of manufacturing operations to emerging economies
    • 4.2.3.2 Focus on production optimization and high R&D investments
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Complexities in integrating pharmaceutical inspection machines
• 4.3 UNMET NEEDS & WHITE SPACES
  • 4.3.1 UNMET NEEDS IN PHARMACEUTICAL INSPECTION MACHINES MARKET
  • 4.3.2 WHITE SPACE OPPORTUNITIES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 BARGAINING POWER OF SUPPLIERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC INDICATORS
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS & FORECAST
  • 5.2.3 TRENDS IN GLOBAL PHARMACEUTICAL INDUSTRY
  • 5.2.4 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
• 5.3 SUPPLY CHAIN ANALYSIS
  • 5.3.1 ROLE IN SUPPLY CHAIN
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
  • 5.5.1 PHARMACEUTICAL INSPECTION MACHINE SUPPLIERS
  • 5.5.2 END USERS
• 5.6 PRICING ANALYSIS
  • 5.6.1 AVERAGE SELLING PRICE TREND FOR PHARMACEUTICAL INSPECTION MACHINES, BY PRODUCT
  • 5.6.2 AVERAGE SELLING PRICE TREND FOR PHARMACEUTICAL INSPECTION MACHINES, BY REGION
  • 5.6.3 AVERAGE SELLING PRICE TREND FOR PHARMACEUTICAL INSPECTION MACHINES, BY END-USE INDUSTRY
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT DATA FOR INSTRUMENTS, APPLIANCES, AND MACHINES FOR MEASURING OR CHECKING (HS CODE: 903180)
  • 5.7.2 EXPORT DATA FOR INSTRUMENTS, APPLIANCES, AND MACHINES FOR MEASURING OR CHECKING (HS CODE: 903180)
  • 5.7.3 IMPORT DATA FOR PARTS AND ACCESSORIES FOR INSTRUMENTS, APPLIANCES, AND MACHINES FOR MEASURING AND CHECKING (HS CODE: 903190)
  • 5.7.4 EXPORT DATA FOR PARTS AND ACCESSORIES FOR INSTRUMENTS, APPLIANCES, AND MACHINES FOR MEASURING AND CHECKING (HS CODE: 903190)
• 5.8 KEY CONFERENCES & EVENTS, 2026-2027
• 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.10 INVESTMENT & FUNDING SCENARIO
• 5.11 CASE STUDY ANALYSIS
• 5.12 IMPACT OF 2025 US TARIFFS ON PHARMACEUTICAL INSPECTION MACHINES MARKET
  • 5.12.1 INTRODUCTION
  • 5.12.2 KEY TARIFF RATES
  • 5.12.3 PRICE IMPACT ANALYSIS
  • 5.12.4 IMPACT ON COUTRY/REGION
  • 5.12.5 IMPACT ON END USE INDUSTRIES
    • 5.12.5.1 Pharmaceutical companies
    • 5.12.5.2 Biotechnology companies
    • 5.12.5.3 Contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs)

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1.1 Machine vision technology
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Advanced sensors & imaging techniques
  • 6.1.3 TECHNOLOGY/PRODUCT ROADMAP
• 6.2 PATENT ANALYSIS
  • 6.2.1 INSIGHTS ON PATENT PUBLICATION TRENDS, TOP APPLICANTS, AND JURISDICTION FOR PHARMACEUTICAL INSPECTION SYSTEMS, JANUARY 2015-APRIL 2026
  • 6.2.2 LIST OF MAJOR PATENTS, 2023-2026
• 6.3 FUTURE APPLICATIONS
  • 6.3.1 AI-POWERED VISUAL DEFECT DETECTION
  • 6.3.2 ADVANCED HYPERSPECTRAL & MULTI-IMAGING INSPECTION
  • 6.3.3 SMART SENSOR-INTEGRATED INSPECTION SYSTEMS
  • 6.3.4 INTEGRATED MULTI-FUNCTION PHARMACEUTICAL INSPECTION PLATFORMS
• 6.4 IMPACT OF AI ON PHARMACEUTICAL INSPECTION MACHINES MARKET
  • 6.4.1 TOP USE CASES & MARKET POTENTIAL
  • 6.4.2 BEST PRACTICES IN PHARMACEUTICAL INSPECTION MACHINES MARKET
  • 6.4.3 CASE STUDIES OF AI IMPLEMENTATION IN PHARMACEUTICAL INSPECTION MACHINES MARKET
  • 6.4.4 INTERCONNECTED ADJACENT ECOSYSTEM & IMPACT ON MARKET PLAYERS
  • 6.4.5 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN PHARMACEUTICAL INSPECTION MACHINES MARKET

7 SUSTAINABILITY & REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS & COMPLIANCE
  • 7.1.1 REGULATORY ANALYSIS
    • 7.1.1.1 North America
    • 7.1.1.2 Europe
    • 7.1.1.3 APAC
  • 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 7.2 INDUSTRY STANDARDS
  • 7.2.1 PHARMACEUTICAL INSPECTION MACHINE PRACTICE STANDARDS
  • 7.2.2 ELECTRICAL AND MACHINERY SAFETY STANDARD - ISO 12100 & EN 60204-1
  • 7.2.3 SOFTWARE LIFECYCLE STANDARD - GAMP 5 & FDA 21 CFR PART 11

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY
  • 8.5.1 REVENUE POTENTIAL
  • 8.5.2 COST DYNAMICS
  • 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

9 PHARMACEUTICAL INSPECTION MACHINES MARKET, BY COMPONENT

• 9.1 INTRODUCTION
• 9.2 PHARMACEUTICAL INSPECTION SYSTEMS
  • 9.2.1 VISION INSPECTION SYSTEMS
    • 9.2.1.1 Multifunctional vision inspection systems
      • 9.2.1.1.1 Versatility and improved production efficiency to drive segmental growth
    • 9.2.1.2 Specialized vision inspection systems
      • 9.2.1.2.1 Stringent quality standards and better patient well-being to propel segment growth
  • 9.2.2 X-RAY INSPECTION SYSTEMS
    • 9.2.2.1 Increasing demand for precise underfill and overfill inspection to aid market growth
  • 9.2.3 LEAK DETECTION SYSTEMS
    • 9.2.3.1 Rising adoption in pharmaceutical applications to drive market growth
  • 9.2.4 METAL DETECTORS
    • 9.2.4.1 Growing need for metal contaminant detection in food & beverage industry to boost demand
  • 9.2.5 CHECKWEIGHERS
    • 9.2.5.1 Increased focus on reducing waste in manufacturing process to aid market growth
  • 9.2.6 COMBINATION SYSTEMS
    • 9.2.6.1 Technological advancements for ensuring thorough quality assessment and regulatory compliance to drive market
  • 9.2.7 OTHER PHARMACEUTICAL INSPECTION SYSTEMS
• 9.3 PHARMACEUTICAL INSPECTION SOFTWARE
  • 9.3.1 RISING NEED TO IMPROVE INSPECTION EFFICIENCY TO PROPEL ADOPTION

10 PHARMACEUTICAL INSPECTION MACHINES MARKET, BY TYPE

• 10.1 INTRODUCTION
• 10.2 FULLY AUTOMATED PHARMACEUTICAL INSPECTION MACHINES
  • 10.2.1 SUPERIOR THROUGHPUT RATES AND DEFECT DETECTION ACCURACY IN HIGH-VISCOSITY SUSPENSIONS TO DRIVE MARKET
• 10.3 SEMI-AUTOMATED PHARMACEUTICAL INSPECTION MACHINES
  • 10.3.1 SIMULTANEOUS INSPECTION CAPABILITIES WITH HIGH STANDARDS OF PHARMACEUTICAL QUALITY CONTROL TO AID MARKET GROWTH
• 10.4 MANUAL PHARMACEUTICAL INSPECTION MACHINES
  • 10.4.1 COST-EFFECTIVENESS TO AUGMENT SEGMENT GROWTH

11 PHARMACEUTICAL INSPECTION MACHINES MARKET, BY PACKAGING TYPE

• 11.1 INTRODUCTION
• 11.2 AMPOULES & VIALS
  • 11.2.1 INCREASING DEMAND FOR VACCINES AND BIOPHARMACEUTICALS TO FUEL MARKET GROWTH
• 11.3 SYRINGES
  • 11.3.1 IMPROVED SAFETY AND INCREASED COMPLIANCE WITH CGMP STANDARDS TO SUPPORT MARKET GROWTH
• 11.4 BOTTLES
  • 11.4.1 RISING DEMAND FOR LIQUID OR SOLID RESIDUE DETECTION TO AUGMENT MARKET GROWTH
• 11.5 BLISTERS
  • 11.5.1 SUPERIOR PRODUCT PROTECTION AND ENHANCED PATIENT COMPLIANCE TO BOOST MARKET GROWTH
• 11.6 OTHER PACKAGING TYPES

12 PHARMACEUTICAL INSPECTION MACHINES MARKET, BY FORMULATION

• 12.1 INTRODUCTION
• 12.2 ORAL FORMULATIONS
  • 12.2.1 TABLETS & CAPSULES
    • 12.2.1.1 Increasing applications in pharmaceutical industry to drive segment
  • 12.2.2 ORAL SOLUTIONS & SUSPENSIONS/SYRUPS
    • 12.2.2.1 Focus on improved product quality and prevention of contamination to fuel segment growth
  • 12.2.3 OTHER ORAL FORMULATIONS
• 12.3 PARENTERAL FORMULATIONS
  • 12.3.1 INCREASED PRODUCTION THROUGHPUT AND REDUCED HUMAN ERRORS TO BOOST SEGMENT GROWTH
• 12.4 OTHER FORMULATIONS

13 PHARMACEUTICAL INSPECTION MACHINES MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 PHARMACEUTICAL COMPANIES
  • 13.2.1 HIGH PREVALENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH
• 13.3 BIOTECHNOLOGY COMPANIES
  • 13.3.1 FOCUS ON REDUCING COUNTERFEIT DRUG PRODUCTION AND IMPROVING PRODUCT QUALITY TO SPUR MARKET GROWTH
• 13.4 CROS & CDMOS
  • 13.4.1 LOW MANUFACTURING COSTS AND HIGH-QUALITY MAINTENANCE TO FUEL MARKET GROWTH

14 PHARMACEUTICAL INSPECTION MACHINES MARKET, BY REGION

• 14.1 INTRODUCTION
• 14.2 NORTH AMERICA
  • 14.2.1 US
    • 14.2.1.1 US to dominate North American pharmaceutical inspection machines market during forecast period
  • 14.2.2 CANADA
    • 14.2.2.1 Focus on better healthcare quality and increased patient safety to support market growth
• 14.3 EUROPE
  • 14.3.1 GERMANY
    • 14.3.1.1 High healthcare spending and presence of key pharmaceutical manufacturers to aid market growth
  • 14.3.2 UK
    • 14.3.2.1 Rising demand for personalized medicines and increasing geriatric population to augment market growth
  • 14.3.3 FRANCE
    • 14.3.3.1 Growth in generic drug market and increased pharmaceutical exports to spur adoption
  • 14.3.4 ITALY
    • 14.3.4.1 Favorable government initiatives and increased private investments to drive market
  • 14.3.5 SPAIN
    • 14.3.5.1 Improved healthcare infrastructure and high prevalence of chronic diseases to boost market growth
  • 14.3.6 REST OF EUROPE
• 14.4 ASIA PACIFIC
  • 14.4.1 CHINA
    • 14.4.1.1 Increased investment in healthcare infrastructure to propel market growth
  • 14.4.2 JAPAN
    • 14.4.2.1 Well-developed pharmaceutical manufacturing industry and stringent healthcare regulations to drive market
  • 14.4.3 INDIA
    • 14.4.3.1 Growing focus on cost-effective branded drug production to fuel market growth
  • 14.4.4 AUSTRALIA
    • 14.4.4.1 High R&D expenditure and technological advancements to fuel market growth
  • 14.4.5 SOUTH KOREA
    • 14.4.5.1 Attractive medical tourism industry and favorable government policies to propel market growth
  • 14.4.6 REST OF ASIA PACIFIC
• 14.5 LATIN AMERICA
  • 14.5.1 BRAZIL
    • 14.5.1.1 Increasing geriatric population and rising per capita income to aid market growth
  • 14.5.2 MEXICO
    • 14.5.2.1 Improving healthcare infrastructure and burgeoning pharmaceutical industry to augment market growth
  • 14.5.3 REST OF LATIN AMERICA
• 14.6 MIDDLE EAST & AFRICA
  • 14.6.1 GCC COUNTRIES
    • 14.6.1.1 Robust economic growth and high public healthcare spending to support market growth

15 COMPETITIVE LANDSCAPE

• 15.1 OVERVIEW
• 15.2 KEY PLAYER STRATEGY/RIGHT TO WIN
• 15.3 REVENUE ANALYSIS, 2023-2025
• 15.4 MARKET SHARE ANALYSIS, 2025
• 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 15.5.1 STARS
  • 15.5.2 EMERGING LEADERS
  • 15.5.3 PERVASIVE PLAYERS
  • 15.5.4 PARTICIPANTS
  • 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 15.5.5.1 Company footprint
    • 15.5.5.2 Region footprint
    • 15.5.5.3 Component footprint
    • 15.5.5.4 Type footprint
    • 15.5.5.5 Packaging type footprint
• 15.6 COMPETITIVE EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 15.6.1 PROGRESSIVE COMPANIES
  • 15.6.2 RESPONSIVE COMPANIES
  • 15.6.3 DYNAMIC COMPANIES
  • 15.6.4 STARTING BLOCKS
  • 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 15.6.5.1 Detailed list of key startups/SMEs
    • 15.6.5.2 Competitive benchmarking of key startups/SMEs
• 15.7 COMPANY VALUATION & FINANCIAL METRICS
  • 15.7.1 FINANCIAL METRICS
  • 15.7.2 COMPANY VALUATION
• 15.8 BRAND/PRODUCT COMPARISON
• 15.9 COMPETITIVE SCENARIO
  • 15.9.1 PRODUCT LAUNCHES
  • 15.9.2 DEALS
  • 15.9.3 EXPANSIONS
  • 15.9.4 OTHER DEVELOPMENTS

16 COMPANY PROFILES

• 16.1 KEY PLAYERS
  • 16.1.1 KORBER AG
    • 16.1.1.1 Business overview
    • 16.1.1.2 Products offered
    • 16.1.1.3 Recent developments
      • 16.1.1.3.1 Product launches
      • 16.1.1.3.2 Deals
    • 16.1.1.4 MnM view
      • 16.1.1.4.1 Right to win
      • 16.1.1.4.2 Strategic choices
      • 16.1.1.4.3 Weaknesses & competitive threats
  • 16.1.2 METTLER-TOLEDO
    • 16.1.2.1 Business overview
    • 16.1.2.2 Products offered
    • 16.1.2.3 Recent developments
      • 16.1.2.3.1 Product launches
    • 16.1.2.4 MnM view
      • 16.1.2.4.1 Right to win
      • 16.1.2.4.2 Strategic choices
      • 16.1.2.4.3 Weaknesses & competitive threats
  • 16.1.3 OMRON CORPORATION
    • 16.1.3.1 Business overview
    • 16.1.3.2 Products offered
    • 16.1.3.3 Recent developments
      • 16.1.3.3.1 Product launches & upgrades
      • 16.1.3.3.2 Deals
    • 16.1.3.4 MnM view
      • 16.1.3.4.1 Right to win
      • 16.1.3.4.2 Strategic choices
      • 16.1.3.4.3 Weaknesses & competitive threats
  • 16.1.4 STEVANATO GROUP
    • 16.1.4.1 Business overview
    • 16.1.4.2 Products offered
    • 16.1.4.3 Recent developments
      • 16.1.4.3.1 Product launches & upgrades
      • 16.1.4.3.2 Deals
    • 16.1.4.4 MnM view
      • 16.1.4.4.1 Right to win
      • 16.1.4.4.2 Strategic choices
      • 16.1.4.4.3 Weaknesses & competitive threats
  • 16.1.5 COGNEX CORPORATION
    • 16.1.5.1 Business overview
    • 16.1.5.2 Products offered
    • 16.1.5.3 Recent developments
      • 16.1.5.3.1 Product launches
      • 16.1.5.3.2 Deals
    • 16.1.5.4 MnM view
      • 16.1.5.4.1 Right to win
      • 16.1.5.4.2 Strategic choices
      • 16.1.5.4.3 Weaknesses & competitive threats
  • 16.1.6 ANTARES VISION GROUP
    • 16.1.6.1 Business overview
    • 16.1.6.2 Products offered
    • 16.1.6.3 Recent developments
      • 16.1.6.3.1 Product launches & upgrades
      • 16.1.6.3.2 Deals
      • 16.1.6.3.3 Expansion
      • 16.1.6.3.4 Other developments
  • 16.1.7 OPTEL GROUP
    • 16.1.7.1 Business overview
    • 16.1.7.2 Products offered
  • 16.1.8 SYNTEGON TECHNOLOGY GMBH
    • 16.1.8.1 Business overview
    • 16.1.8.2 Products offered
    • 16.1.8.3 Recent developments
      • 16.1.8.3.1 Product launches
  • 16.1.9 JEKSON VISION
    • 16.1.9.1 Business overview
    • 16.1.9.2 Products offered
  • 16.1.10 ACG
    • 16.1.10.1 Business overview
    • 16.1.10.2 Products offered
  • 16.1.11 BREVETTI CEA SPA
    • 16.1.11.1 Business overview
    • 16.1.11.2 Products offered
    • 16.1.11.3 Recent developments
      • 16.1.11.3.1 Deals
  • 16.1.12 ROQUETTE FRERES
    • 16.1.12.1 Business overview
    • 16.1.12.2 Products offered
  • 16.1.13 TOFFLON LIFE SCIENCE
    • 16.1.13.1 Business overview
    • 16.1.13.2 Products offered
  • 16.1.14 PRODITEC
    • 16.1.14.1 Business overview
    • 16.1.14.2 Products offered
  • 16.1.15 WIPOTEC GMBH
    • 16.1.15.1 Business overview
    • 16.1.15.2 Products offered
  • 16.1.16 CMP PHARMA S.R.L.
    • 16.1.16.1 Business overview
    • 16.1.16.2 Products offered
    • 16.1.16.3 Recent developments
      • 16.1.16.3.1 Expansions
• 16.2 OTHER PLAYERS
  • 16.2.1 KEYENCE CORPORATION
  • 16.2.2 CASSEL MESSTECHNIK GMBH
  • 16.2.3 THERMO FISHER SCIENTIFIC INC.
  • 16.2.4 LOMA SYSTEMS
  • 16.2.5 VITRONIC DR.-ING. STEIN BILDVERARBEITUNGSSYSTEME GMBH
  • 16.2.6 MINEBEA INTEC GMBH
  • 16.2.7 MARCHESINI GROUP S.P.A.
  • 16.2.8 N.K.P. PHARMA PVT. LTD.
  • 16.2.9 SPAN SYSTEMS

17 RESEARCH METHODOLOGY

• 17.1 RESEARCH DATA
  • 17.1.1 SECONDARY DATA
    • 17.1.1.1 Key data from secondary sources
  • 17.1.2 PRIMARY DATA
    • 17.1.2.1 Key data from primary sources
    • 17.1.2.2 Key industry insights
• 17.2 MARKET SIZE ESTIMATION
• 17.3 MARKET BREAKDOWN & DATA TRIANGULATION
• 17.4 MARKET RANKING ANALYSIS
• 17.5 STUDY ASSUMPTIONS
• 17.6 RISK ASSESSMENT
• 17.7 LIMITATIONS
  • 17.7.1 METHODOLOGY-RELATED LIMITATIONS

18 APPENDIX

• 18.1 DISCUSSION GUIDE
• 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 18.3 CUSTOMIZATION OPTIONS
• 18.4 RELATED REPORTS
• 18.5 AUTHOR DETAILS